Expression Pathology Obtains Maryland Funding to Develop Breast Cancer Test

GAITHERSBURG, Md.--(BUSINESS WIRE)--Expression Pathology Inc. (EPI), a leader in tissue protein analysis, has obtained $125,000 from the State of Maryland to develop a quantitative test for HER2 protein, an important biomarker in breast cancer tissue samples. The funding is part of the Maryland Technology Development Corporation’s Maryland Technology Transfer Fund (TEDCO MTTF) and the Maryland Venture Fund’s Challenge Investment Program.

Back to news